

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant: Douglas J. ALLEN, et al. Group Art Unit: 1618
Serial No.: 10,613,619 Examiner: Blessing M. Fubara
Application Date: July 3, 2003 Conf No.: 4376
For: 2-METHYL-THIENO-BENZODIAZEPINE FORMULATION
Docket No.: X-11666C

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Under the guidelines of 37 C.F.R. 1.97, Applicants submit a copy of each of the non-US patent documents listed on the attached Form PTO-1449 (modified) for consideration by the Examiner.

Applicants wish to bring to the attention of the Office that WO2006/073886 is related to olanzapine pamoate dihydrate, is owned by Eli Lilly and Company, and has just entered the National Phase in the United States via the PCT. Hence, WO 2006/073886 (USSN 11/722228) is now co-pending with the present patent application which is also owned by Eli Lilly and Company.

In addition, Applicants wish to bring to the attention of the Office that an English translation of the French reference, E. Saias, et al., *Annales Pharmaceutiques Francaises*, 27(9-10), 557-570 (1969), listed in the Form 1449 is attached herewith.

Since this Statement is being filed after the period specified in §1.97(b), but before the mailing date of a final action or a notice of allowance, please charge the amount of \$180.00, the fee under 37 C.F.R. 1.17(p), and charge any additional fees which may be required by this or any other related paper, or credit any overpayment to Deposit Account No. 05-0840.

Applicants request consideration of this information.

Respectfully submitted,

/Nelsen L. Lentz/

Nelsen L. Lentz
Attorney for Applicants
Registration No. 38,537
Phone: 317-276-1207

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

June 27, 2007
